PANDORA GENOMICS

PGxReport™ – Clopidogrel
Drug Sensitivity Assay Results

References

1. Chang TK, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. *Cancer Research* (1993) **53**, 5629-37.
2. Chang TK, Yu L, Goldstein JA, Waxman DJ. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. *Pharmacogenetics* (1997) **7**, 211-21.
3. This article states there is no effect of the polymorphisms on toxicity of cyclophosphamide: Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. *Pharmacogenetics and Genomics* (2008) **18**, 515-23.
4. Goe PP, Su HI, Gray RJ, Gimotty PA, Horn M, Aplenc R, Vaughan WP, Tallman MS, Rebbeck TR, DeMichele A. Cyclophosphamide – metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. *Breast Cancer Research* (2010) **12**, R26.
5. Helsby NA, Hui C-Y, Goldthorpe MA, Coller JK, Soh MC, Gow PJ, De Zoysa JZ, Tingle MD. The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. *British Journal of Clinical Pharmacology* (2010) **70**, 844–850.
6. Mo S-L, Liu Y-H, Duan W, Wei MQ, Kanwar JR, Zhou S-F. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. *Clinical Pharmacology & Therapeutics* (2007) **81**, 557-66.
7. Nakajima M, Komagata S, Fujiki Y, Kanada Y, Ebi H, Itoh K, Mukai H, Yokoi T, Minami H. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. *Pharmacogenetics and Genomics* (2007) **17**, 431-45.
8. Ngamjanyaporn P, Thakkinstian A, Verasertniyom O, Chatchaipun P, Vanichapuntu M, Nantiruj K, Totemchokchyakarn K, Attia J, Janwityanujit S. Pharmacogenetics of cyclophosphamide and CYP2C19 polymorphism in Thai systemic lupus erythematosus. *Rheumatology International* (2011) **31**, 1215-8.
9. Ren S, Yang J-S, Kalhorn TF, Slattery JT. Oxidation of Cyclophosphamide to 4-Hydroxycyclophosphamide and Deschloroethylcyclophosphamide in Human Liver Microsomes. *Cancer Research* (1997) **57**, 4229.
10. Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. *Oncogene* (2006) **25**, 1679-1691.
11. Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, Décosterd L, Blievernicht J, Saussele T, Günthard HF, Schwab M, Eichelbaum M, Telenti A , Zanger UM. Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV-infected Individuals Genetic Variability of CYP2B6 and Efavirenz Plasma Levels. *Clinical Pharmacology & Therapeutics* (2007) **81**, 557-566.
12. Timm R, Kaiser R, Lötsch J, Heider U, Sezer O, Weisz K, Montemurro M, Roots I, Cascorbi I. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. *The Pharmacogenomics journal* (2005) **5**, 365-373.
13. Xie H-J, Yasar Ü, Lundgren S, Griskevicius L, Terelius Y, Hassan M, Rane A. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. *The Pharmacogenomics journal* (2003) **3**, 53–61.

FIG. 7-10